EBITDA was Rs. 2,359.6 crore in the quarter ended September 30, 2025
SMDC is a participating authority under Pharmaceutical Inspection Cooperation Scheme (PIC/S)
The observations are procedural in nature and will be responded to within the stipulated time
Diroximel fumarate delayed-release capsules, 231 mg, are indicated for the treatment of relapsing forms of multiple sclerosis
OncoMate MSI Dx Analysis System is a PCR-based assay designed to evaluate MSI status in tumor tissue
The results demonstrated meaningful reductions in the severity of involuntary movements and notable improvements in patient-reported quality of life
The FDA setback highlights ongoing tensions between patient needs, regulatory processes, and the use of real-world evidence in evaluating treatments for rare diseases
The approval granted with zero supplementation requests is an important milestone in Glenmark’s respiratory pipeline
Subscribe To Our Newsletter & Stay Updated